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Effect of immunosuppression on damage, leukocyte infiltration,
and regeneration after severe warm ischemia/reperfusion renal
injury.
Background. Post-ischemia/reperfusion (I/R) damage, ac-
companied by leukocyte infiltration, is unavoidable in renal
transplantation, as is the need for immunosuppressive treat-
ment. Influence of immunosuppressive treatment on post-I/R
renal damage, nonalloimmune cellular infiltration, and regen-
eration is not well studied.
Methods. Uninephrectomized inbred LEW rats were sub-
mitted to warm renal ischemia of 45 minutes/60 minutes, and
received different immunosuppressive regimens: cyclosporine
(CsA) 10 mg/kg/day subcutaneously in the neck daily, or myco-
phenolate mofetil (MMF) 20 mg/kg/day by daily oral gavage.
Control animals underwent sham operation (unilateral nephrec-
tomy) with immunosuppressive treatment or ischemia with ve-
hicle administration. In addition the effect of MMF/mycophe-
nolic acid (MPA) on renal tubule cell proliferation in culture
was studied with bromodeoxyuridine incorporation.
Results. The post-I/R interstitial cellular infiltration/prolifer-
ation consisted mainly of mononuclear leukocytes [first mono-
cytes/macrophages (Mo/M) followed by CD4 cells]. This
mononuclear cell infiltration became apparent 24 hours after
injury at the time of acute tubular necrosis, and was most promi-
nent during the phase of regeneration. Severe I/R combined
with CsA aggravated morphologic damage and dysfunction,
without effect on tubular cell proliferation and tubular regener-
ation. Early leukocyte infiltration was qualitatively and quanti-
tatively comparable to control animals, yet decreased moder-
ately later in time. In contrast, MMF in combination with severe
I/R did not influence initial morphologic damage and dysfunc-
tion. Although the initial leukocyte infiltration was comparable
to control animals, the subsequent mononuclear cell accumula-
tion, especially CD4 T cells decreased dramatically during
MMF treatment. This was concomitant with a decrease of tubu-
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lar cell proliferation and hence tubular regeneration. Increasing
MPA concentrations in renal tubular cell culture caused a
significant decrease in total cell number, and an almost arrest
of bromodeoxyuridine incorporation, as measurement of cell
proliferation.
Conclusion. Immunosuppressive treatment with CsA or MMF
affected significantly and in a different manner post-I/R renal
morphologic damage, interstitial leukocyte, accumulation and
regeneration.
A certain degree of ischemia/reperfusion (I/R) injury
is always present in renal transplantation, as is the need
for immunosuppressive treatment. The highly perfused
kidney is particularly vulnerable to the deleterious ef-
fects of renal hypoperfusion (ischemia) and to many
toxic substances, or a combination of both. Delayed graft
function (DGF) of renal allografts is still frequently ob-
served in the immediate posttransplant period, very of-
ten as a result from postischemic acute tubular necrosis
(ATN), drug nephrotoxicity, acute rejection or combina-
tions of these factors [1, 2]. It is becoming increasingly
apparent that DGF can also be associated with more
ominous consequences like acute and chronic rejection,
and particular poor long-term renal graft survival [2, 3].
Although the number of acute rejections have been dra-
matically reduced over the last 10 years by optimization
of prophylactic immunosuppressive regimens, the fre-
quency of DGF has remained. In the Eurotransplant area
it is still 33% [4]. Moreover, due to increased organ short-
age, increased use of marginal donors and nonheart-
beating donors, the problem of DGF and its related
problems will persist. The clinical impression exists that
the structural and functional recovery from the unavoid-
able posttransplant ischemia seems to be delayed, com-
pared to nontransplant-related acute renal failure (ARF)
[5]. What kind of role, if any, immunosuppressive drugs
play in this recovery remains unexplored.
A manifest and intriguing effect during ATN and re-
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pair is the prompt appearance of inflammatory cells,
immediately following injury, disappearing when the re-
generation is complete. This post-I/R infiltrate consists
of an accumulation of monocytes /macrophages (Mo/M)
followed by helper T cells, most prominent at the time
and place of regeneration, when functional recovery has
already taken place [6, 7]. Although the literature on the
possible role of these interstitial leukocytes is abundant,
their exact initiating and resolving mechanisms, and their
effect on early and final outcome of ARF, are still unclear
[8]. It is reasonable to consider a possible role of immu-
nosuppressive drugs, by their direct action on leukocytes
(especially lymphocytes) and their function, in the post-
I/R renal injury and repair.
Current immunosuppressive therapy is rather unspe-
cific and affects defense mechanisms. Traditional initial
immunosuppressive regimens in nonimmunized cadaveric
first kidney transplant recipients implies steroids, calcineuri
ninhibitors [cyclosporine A (CsA), tacrolimus] and antipro-
liferative agents [mycophenolate mofetil (MMF), azathio-
prine]. Calcineurin inhibition by CsA, still one of the
most widely used immunosuppressive drug in renal
transplantation, prevents interleukin-2 (IL-2) gene tran-
scription, a cytokine with a pivotal role in helper T-cell
activation and clonal expansion of helper and cytotoxic
T cells [9]. CsA also interferes with the T cell–epithelial
cell adhesion by altering leukocyte function-associated
molecule-1 (LFA-1) and intercellular adhesion mole-
cule-1 (ICAM-1) expression [10]. Among many side ef-
fects, acute cyclosporine nephrotoxicity, resulting from
vasoconstriction of the afferent arteriole may exacerbate
ATN in cadaveric renal transplantation [11].
MMF is a new immunosuppressive agent recently re-
leased for clinical use, in conjunction with steroids and
cyclosporine, for the prevention of acute rejection in
renal transplant patients [12]. MMF is a prodrug, the
active drug being mycophenolic acid (MPA), which itself
is a noncompetitive reversible inhibitor of the enzyme
inosine monophosphate dehydrogenase (IMPDH). This
enzyme is a key enzyme in the de novo purine synthesis
pathway, to which lymphocytes are more dependent than
other cells. Inhibition of IMPDH has little impact on
proliferation in most eukaryotic cells due to the existence
of a salvage pathway, in contrast to lymphocytes where
MPA specifically inhibits their proliferation, thus lim-
iting cell-mediated immune mechanisms [13]. In vitro,
MMF inhibits de novo B and T lymphocyte proliferation
in response to polyclonal T- and B-cell mitogens, and
decreases the generation of cytotoxic T cells [14]. MMF
also decreases homing of monocytes to the endothelium
[15]. Additional anti-inflammatory actions may derive
from inhibition of adhesion molecules, limiting the mi-
gration of lymphocytes and other inflammatory cells [16].
MMF inhibits smooth muscle cell proliferation in rat
aortic allografts [17], and in rat remnant kidney [18].
Among side effects gastrointestinal toxicity is frequently
observed, but nephrotoxicity is not reported.
In this paper, the functional and morphologic evolu-
tion of ATN, the rate of regeneration, and the pattern
and degree of interstitial leukocyte infiltration/prolifera-
tion after severe warm I/R-induced renal injury is studied
in rats treated with two different immunosuppressive
drug regimens (CsA and MMF).
METHODS
Animals
After overnight fasting, the surgical procedures were
carried out under anesthesia with sodium penthobarbi-
tone (60 mg/kg) in inbred male LEW rats (220 to 260 g).
A midline abdominal incision was made and heparin (50
IU, intraperitoneally) was administered. In order to help
to maintain thermoregulation during ischemia, the ab-
dominal contents were repositioned and covered with a
warm wet dressing. Left renal ischemia was performed
by cross-clamping the left renal pedicle for 60 minutes
with a microvascular clamp, followed by right nephrec-
tomy at the end of the ischemia period. In nonischemic
control animals, the left renal pedicle was dissected, but
not clamped, followed by a right nephrectomy. Careful
dissection was carried out to preserve the blood supply
to the adrenal glands. The kidneys were inspected for
ischemia as well for adequate reperfusion for 2 minutes.
Postoperative animals were allowed to recover, each in
a separate cage, at constant temperature (18C) and hu-
midity (45%) on a 12-hour light/dark cycle. They received
free tap water ad libitum and paired feeding using stan-
dard laboratory rat pellets. This paired feeding is of partic-
ular importance since CsA induces anorexia and MMF
may have gastrointestinal side effects. Animals were
weighed and inspected daily. For each experimental time
point, four animals were sacrificed (day 1, 2, 3, 5, 7, and
10). Blood samples were taken by heart puncture. All
procedures were carried out in accordance with the Na-
tional Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals No. 85-23 (1985), and
with approval of the Ethical Committee of the University
of Antwerp.
Experimental groups: Immunosuppression
The daily administration of CsA (Sandimmun, Novar-
tis, Basel, Switzerland) (10 mg/kg/day) was given subcuta-
neously in the neck, starting at the end of the warm ischemic
period of 60 minutes. Animals were randomly assigned to
four groups: (1) nephrectomy  vehicle (cremophore)
(N  24), (2) nephrectomy and CsA (N  24), (3)
nephrectomy and renal ischemia  vehicle (N  24),
and (4) nephrectomy, renal ischemia and CsA (N  24).
In a pilot experiment, the use of a previous proven
immunosuppressive dose of 20 mg/kg/day MMF in com-
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bination with 60 minutes I/R proved to be lethal for a
majority of animals, due to gastrointestinal toxicity (ul-
cers, diarrhea). Control animals in this experiments sus-
tained the dose very well. As a drug dose of less than
20 mg/kg/day seemed not immunosuppressive in litera-
ture, we decided to conduct the final experiment using
45 minutes I/R: (1) nephrectomy  vehicle (N  24),
(2) nephrectomy and MMF (N  24), (3) nephrectomy
and renal ischemia vehicle (N  24), and (4) nephrec-
tomy, renal ischemia and MMF (N  24). MMF was
given daily by oral gavage, starting as soon the animals
had recovered from anesthesia. The experiments with
CsA either MMF were conducted as separate experi-
ments, each with their own control groups. Accordingly,
the statistical, descriptive analysis, and conclusions were
performed separately.
Biochemical determinations
Serum was obtained at sacrifice and stored at 20C
until use. Serum creatinine values were determined in
duplicate using a colorimetric method as modified by
Jaffe´ (Creatinine Merckotest, Diagnostica Merck, Darm-
stadt, Germany).
Tissue collection and fixation
Immediately after sacrifice, five sagittal tissue sections
(1 mm thick) were collected from the left kidney and
fixed in formalin calcium, methacarn, and Dubosq Brazil
fixative. Two sections were stored in liquid nitrogen.
Morphologic analysis of tubular injury, regeneration,
cell proliferation, and apoptosis
The degree of injury in different tubular compart-
ments was established on periodic acid-Schiff reagent
(PAS)-hematoxylin-proliferating cell nuclear antigen
(PCNA)–stained sections of methacarn-fixed and paraf-
fin-embedded renal tissue. Proliferation was determined
by immunohistochemical staining for the PCNA using
the PC10 monoclonal antibody (Dako, Glostrup, Den-
mark). This PCNA is expressed when cells are going into
DNA synthesis (cell division, DNA repair, apoptosis). Sec-
tions were counterstained with PAS. Nuclei were stained
with methyl green. Histologic damage of the kidney was
scored semiquantitatively, as previously described
[19, 20]. Fifty proximal tubules in the outer stripe of the
outer medulla (most sensitive zone for ischemic injury)
were assigned as (1) tubules with normal appearance;
(2) tubules with signs of sublethal injury (loss of apical
brush border); (3) tubules with 25% to 75% tubular cell
loss; (4) totally (100%) necrotic tubules (total destruc-
tion of all epithelial cells, naked basement membrane);
and (5) tubules with signs of early regeneration (tubules
without brush border, lined with a flat epithelium con-
taining cells with large dark nuclei (PCNA) and a vary-
ing degree of cytoplasmatic volume. The proliferation
was measured by counting the number of PCNA-immu-
noreactive nuclei in 25 circular-shaped proximal tubules.
Apoptosis was investigated tissue samples of day 2
and 10 after I/R with different methods: terminal deoxy-
nucleotidyl transferase-mediated uridine triphosphate
nick end labeling (TUNEL)-reaction, caspase-3 immuno-
histochemistry, and direct visualization of apoptotic bod-
ies in tubular cell by hematoxylin-eosin (H&E) staining.
Renal adhesion/ infiltration: Leukocyte cell markers
Immunohistochemical detection of Mo/M was per-
formed on methacarn-fixed, paraffin-embedded renal tis-
sue sections using the ED-1 monoclonal antibody (Serotec,
Oxford, UK). This antibody is directed to a cytoplasma-
tic antigen of tissue macrophages and monocytes [21].
Sections (4 m) were mounted on poly-l-lysine–coated
microscopic slides and treated for 5 minutes with 0.003%
trypsin III (Sigma Chemical Co., St. Louis, MO, USA)
in 10 mmol/L Tris-HCl buffer, pH7.3. After washing in
Tris saline buffer (TSB) (0.01 mol/L Tris-HCl, pH 7.6,
in 0.9% NaCl) and treatment with normal horse serum
(1/5), the sections were incubated overnight with the
primary antibody ED-1.
T lymphocytes (helper T cells, W3/25; suppressor/cyto-
toxic T cells, OX-8) and B lymphocytes (OX-33) were
demonstrated on 5 m renal tissue cryosections prefixed
in 4% formaldehyde (BDH Chemical Ltd., Poole, UK)
buffered with 0.1 mol/L Na-cacodylate, pH 7.4, containing
1% CaCl2. Sections were incubated overnight with W3/25
(1/800), OX-8 (1/400), or OX-33 (1/100) (Serotec). Ap-
propriate antibody dilutions were determined in prelimi-
nary experiments. The W3/25 monoclonal antibody rec-
ognizes the rat CD4-equivalent present on T-helper cells
[22] and on macrophages [23]. The OX-8 monoclonal
antibody reacts with T-suppressor/cytotoxic and natural
killer cells, and is directed to the rat CD8-equivalent
[24]. The OX-33 monoclonal antibody reacts with only
peripheral B cells [25]. Endogenous tissue peroxidase
activity was inhibited by immersion in methanol for 15
minutes, followed by 30 minutes incubation with 0.03%
H2O2 in TSB. After washing, subsequent incubations were
performed with the avidin-biotin peroxidase complex
(Vectastain, Vector Laboratories, Inc., Burlingame, CA,
USA) and 9-amino-ethylcarbazole as the chromogen
supplemented with the H2O2 as substrate. As controls,
a spleen section of the rat was also stained. Nuclei were
counterstained with methyl green. Positive cells were
counted in 20 fields of 0.16 mm2 randomly chosen outer
stripe of the outer medulla microscopic fields (magnifi-
cation, 125) in each animal and data were expressed
as positive cells per mm2.
Histochemical detection of polymorphonuclear (PMN)
cells was performed on methacarn-fixed, paraffin-embed-
ded renal tissue sections. The H&E staining was used to
identify and to quantify the infiltration of PMN cells, based
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upon the localization of the cell and morphology of the
nucleus of the cell. Positively stained cells were quantified
in 75 randomly chosen microscopic fields (magnification,
1000) in cortex, outer stripe of the outer medulla (med-
ullary rays), and inner medulla, expressed as positive cells
per mm2.
Human renal tubule cell proliferation in culture
Human proximal and distal tubular cells were pre-
pared after tumor nephrectomy from those portions of
the human kidney not involved in renal cell carcinoma
and processed in a sterile manner. Cortex and outer
stripe of the outer medulla were dissected, cut into pieces
of 1 mm3 and digested in RPMI 1640 containing colla-
genase D solution (Roche, Ottweiler, Germany), supple-
mented with DNAse (Sigma Chemical Co.). The suspen-
sion was shaken vigorously for 2 hours at 37C and sieved
through a 120 m sieve. The resulting single cell suspen-
sion was loaded on top of a discontinuous Percoll (Phar-
macia, Uppsala, Sweden) gradient with densities 1.04
and 1.07 g/mL. After centrifugation, cells from the inter-
section were carefully aspirated, washed and brought
into culture as a mixed population of proximal tubular,
distal tubular, and collecting duct cells. Cells were seeded
in 48-well plates (12,500 cells/well) in	-minimal essential
medium (MEM) (Life Technologies, Rockville, MD,
USA), modified according to Gibson d’Ambrosio, sup-
plemented with 10% fetal calf serum and different con-
centrations (50, 25, 2.5, 0.25 and 0 mol/L) of MPA
(Sigma Chemical Co.). The control cells (0 mol/L
MPA) were incubated with the same amount of metha-
nol. The cells were grown at 37C and 5% CO2 in a
humidified atmosphere for 5 days.
For cell count, cells of two wells per MPA concentra-
tion were trypsinized and counted in a hemocytometer
on day 3 and day 4. Proliferation was measured with a
cell proliferation enzyme-linked immunosorbent assay
(ELISA) based on bromodeoxyuridine incorporation
(Roche, Mannheim, Germany). Cells of 5 wells per MPA
concentration were incubated with the bromodeoxyuri-
dine label for 24 hours between the two cell counts.
The ELISA was performed according to manufacturer
instructions. Proliferation in the presence of different
concentrations of MPA was expressed as percentage of
the proliferation in the control cultures.
Statistics
Data are presented as means  standard deviation.
They were compared with a one-way analysis of variance
(ANOVA) analysis and a Student-Newman-Keuls test
was used to prove qualitative differences by using the
software package SPSS. Significant differences were an-
ticipated when P 
 0.05.
Correlation testing was performed between func-
tional, morphologic, and severity of leukocyte infiltrate.
Bivariate correlation testing was performed using SPSS
10.1 software. The complete data set was analyzed with
parametric (Pearson) and nonparametric (Spearman’s
rho) correlation coefficient testing. Test of significance
was two-tailed.
RESULTS
Cyclosporine: Kidney function and morphology
Nonischemic uninephrectomized rats maintained nor-
mal renal function during the whole study period, unaf-
fected by CsA or vehicle (data not shown). Uninephrec-
tomized rats submitted to 60 minutes warm renal ischemia
without immunosuppression developed sustained severe
ARF, which was significantly more pronounced in CsA
group after 48 hours (serum creatineischemia day 2  4.0 
1.98 mg/dL vs. serum creatinineischemiaCsA day 2  7.2  0.31
mg/dL; P 
 0.05). In the ischemia group, in the absence
of CsA, functional recovery of the kidney started after day
2 and was complete at day 7 (serum creatinineischemia day 7 
1.06  0.11 mg/dL; P 
 0.05). In the group with a daily
administration of CsA, 10 mg/kg/day, recovery of renal
function also started after day 2, but was not complete at
the end of the study period (serum creatinineischemia day 10 
1.05  0.25 mg/dL vs. serum creatinineischemiaCsA day 10 
1.65  0.5 mg/dL; P 
 0.05) (Fig. 1A).
Nonischemic uninephrectomized rats maintained nor-
mal, very modest tubular proliferation activity (PCNA po-
sitivity) during the whole study period, unaffected by CsA
or vehicle (data not shown). In Figure 1, their mean is
presented as controls. In uninephrectomized rats submitted
to warm renal ischemia for 60 minutes without immunosup-
pression, proliferation started already on day 1 with a maxi-
mum on day 3. Although initially unaffected, tubular cell
proliferation (PCNA) was significantly increased from
day 5 to day 10 in CsA-treated post-I/R rats [PCNA
number positive nuclei per cross-sectionischemia day 5  2.4 
1.8 vs. PCNAischemiaCsA day 5  4.4  0.2 (P 
 0.05);
PCNAischemia day 7  0.2  0.4 vs. PCNAischemiaCsA day 7 
2.0  1.0 (P 
 0.05); PCNAischemia day 10  0.1  0.1 vs.
PCNAischemiaCsA day 10  0.4  0.2 (P 
 0.05)] (Fig. 1B).
In nonischemic uninephrectomized rats treated with
CsA or vehicle, no damaged, hence no regenerating, tu-
bules were demonstrated (data not shown). Uninephrec-
tomized rats submitted to warm renal ischemia for 60
minutes without immunosuppression sustained severe
ATN at 24 hours post-ischemia with more than 60% of
proximal tubular cells in the outer stripe of outer medulla
completely damaged (Fig. 1C). CsA treatment resulted
in even greater and sustained damage [% totally necrotic
tubulesischemia day 1  59.5  13.1% vs. ischemiaCsA day 1  90.0
5.3% (P 
 0.05); ischemia day 2  20.7  22.3% vs.
ischemiaCsA day 2  94.0  4.1% (P 
 0.05)], but unimpaired
regeneration, even enhanced [% of tubules with signs
of early regenerationischemia day 5  56.0  10.2% vs.
Ysebaert et al: Immunosuppression and postischemic renal damage, regeneration, and infiltration868
Fig. 1. Effect of immunosuppressive dose of
cyclosporine A (CsA) on post-ischemia/reper-
fusion (I/R) renal function (A ), tubular prolif-
erative activity [proliferating cell nuclear anti-
gen (PCNA)] (B ), and tubular damage and
regeneration (different degrees of tubular ne-
crosis and regeneration) (C ). Values are ex-
pressed as mean  SD. *P 
 0.05. Control
is uninephrectomy without ischemia on the
remaining kidney but with CsA.
ischemiaCsA day 5  82.0  8.1% (P 
 0.05)]. The number of
tubules with complete brush border after 10 days was
less compared to control animals [% of tubules with normal
appearanceischemia day 10  47.0  9.8% vs. ischemiaCsA day 10 
21.0  5.3% (P 
 0.05)].
With either method used, it was difficult to separate
apoptosis from the overwhelming necrosis on day 2 post-
I/R. However, no differences were found in apoptosis
with either method, not on day 2 and not on day 10 post-
I/R.
Mycophenolate mofetil: Kidney function
and morphology
Nonischemic uninephrectomized rats maintained nor-
mal renal function during the whole study period, unaf-
fected by MMF or vehicle (data not shown). Uninephrec-
tomized rats submitted to warm renal ischemia for 45
minutes without immunosuppression developed severe
ARF, but in contrast to CsA, ARF and functional recov-
ery in MMF group were not different from post-I/R
controls (Fig. 2A).
The proliferation activity (PCNA), however, was sig-
nificantly diminished at a time of expected highest ac-
tivity in MMF-treated rats [PCNAischemia day 2  25.3 
7.4 vs. PCNAischemiaMMF day 2  6.3  2.5 (P 
 0.05);
PCNAischemia day 3  50.0  12.8 vs. PCNAischemiaMMF day 3 
23.5  11.7 (P 
 0.05)], resulting in delayed tubular
regeneration (Fig. 2B).
In nonischemic uninephrectomized rats treated with
MMF or vehicle, no damaged, hence no regenerating, tu-
bules were demonstrated (data not shown). Uninephrec-
tomized rats submitted to warm renal ischemia for 45
minutes without immunosuppression sustained severe
ATN at 24 hours post-ischemia with almost 70% of prox-
imal tubuluar cells in the outer stripe of the medulla
completely damaged (Fig. 2C). In MMF-treated rats,
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Fig. 2. Effect of immunosuppressive dose of
mycophenolate mofetil (MMF) on post-isch-
emia/reperfusion (I/R) renal function (A ), tu-
bular proliferative activity [proliferating cell
nuclear antigen (PCNA)] (B ), and tubular
damage and regeneration (different degrees
of tubular necrosis and regeneration) (C ).
Values are expressed as mean  SD. *P 

0.05. Control is uninephrectomy without isch-
emia on the remaining kidney but with MMF.
initial damage (ATN) was similar to non-MMF post-I/R
kidneys at day 1, but the impaired proliferation activity
(PCNA) resulted in delayed tubular regeneration, so
that after 2 to 3 days, significant more tubules remained
totally necrotic [% totally necrotic tubules ischemia day 2 
25.0  9.6% vs. ischemia  MMF day 2  40.0  17.3% (P 

0.05); ischemia day 3  0.0  0.0% vs. ischemia  MMF day 3  7.0 
4.0% (P 
 0.05)]. After 7 to 10 days, fewer tubules
were completely regenerated [% of tubules with normal
appearance ischemia day 7  62.5  5.4% vs. ischemia  MMF day 7 
18.0  7.5% (P 
 0.05); ischemia day 10  60.0  9.5% vs.
ischemia  MMF day 10  34.0  7.6% (P 
 0.05)].
With either method used, it was difficult to separate
apoptosis from the overwhelming necrosis on day 2 post-
I/R. However, no differences in apoptosis were found with
either method, not on day 2, not on day 10 post-I/R.
Cyclosporine: Intrarenal leucocytes accumulation
Polymorphonuclear cells (H&E staining). The num-
ber of PMNs in post-I/R kidneys with immunosuppres-
sion was comparable to their post-I/R controls. They
remain scarce and their number was even never signifi-
cantly different from nonischemic controls (Fig. 3A).
Monocytes/macrophages (ED-1 staining). In unine-
phrectomized rats submitted to warm renal ischemia for
60 minutes without CsA, Mo/M were already observed
after 24 hours, most prominent at day 5 and tended to
disappear after 10 days. Although the early (
day 2)
infiltration was unaffected, treatment with CsA re-
sulted in significant diminished Mo/M infiltration at
day 5 [ED-1ischemia day 5  1034  160 cells/mm2 vs.
ED-1ischemia day 5CsA  261  27 cells/mm2 (P 
 0.05)] (Fig.
3B).
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Fig. 3. Effect of cyclosporine A (CsA) on renal
interstitial leukocyte infiltration in the outer
stripe of the medulla of postischemic rats (ex-
pressed as number/mm2). (A ) Polymorphonu-
clear (PMN) cells. (B ) ED-1, monocytes/mac-
rophages. (C ) W3/25, CD4 helper T cells
(and to some extent monocytes/ macrophages).
(D ) OX-8, suppressor/cytotoxic T cells. Val-
ues are expressed as mean  SD. *P 
 0.05;
**P 
 0.01. Control is uninephrectomy with-
out ischemia on the remaining kidney but with
CsA.
Lymphocytes (W3/25, OX-8, OX-33 staining). Al-
though the early (
day2) appearance of the lymphocytes
in the interstitium was unaffected, the number of intrare-
nal helper T cells (W3/25) was significantly reduced in
CsA-group [W3/25ischemia day 5  1603  201 cells/mm2 vs.
W3/25ischemia day 5CsA 201  67 cells/mm2 (P 
 0.01);
W3/25ischemia day 10  1889  603 cells/mm2 vs.
W3/25ischemia day 10CsA 651  105 cells/mm2 (P 
 0.05)],
while T-suppressor/cytotoxic cells (OX-8) were not dif-
ferent from controls (Fig. 3C and D).
No B cells (OX-33) were present in controls nor in
the CsA-treated group (data not shown).
Mycophenolate mofetil: Intrarenal
leukocytes accumulation
Polymorphonuclear cells (H&E staining). The num-
ber of PMNs in post-I/R kidneys with immunosuppres-
sion was comparable to their post-I/R controls. They
remain scarce and their number was even never signifi-
cantly different from nonischemic controls (Fig. 4A).
Monocytes/macrophages (ED-1 staining). In unine-
phrectomized rats submitted to warm renal ischemia for
45 minutes without MMF, Mo/M were already ob-
served after 24 hours, most prominent at day 5 and tended
to disappear after 10 days. Although the early (
day 2)
infiltration was unaffected, immunosuppressive treat-
ment resulted in significant diminished Mo/M infil-
tration [ED-1ischemia day 3  401  123 cells/mm2 vs.
ED-1ischemiaMMF day 3  94  29 cells/mm2 (P 
 0.05)
(ED-1ischemia day 5 521 84 cells/mm2 vs. ED-1ischemia day 5MMF
85  32 cells/mm2 (P 
 0.01)] (Fig. 4B).
Lymphocytes (W3/25, OX-8, OX-33 staining). Under
MMF treatment, the number of intrarenal T cells in
the interstitium remained unchanged compared to the
nonischemic controls. Indeed, total blockade of T-cell
accumulation was observed, both helper T cells (from
day 5) and suppressor/cytotoxic T cells (from day 2)
within the post-I/R kidney [W3/25 ischemia day 10  1632 
122 cells/mm2 vs. W3/25ischemia day 10MMF 136  2 cells/mm2
(P 
 0.01); OX-8 ischemia day 10  60.2  11.7 cells/mm2 vs.
OX-8ischemia day 10MMF 3.8  2.9 cells/mm2 (P 
 0.001)] (Fig.
4C). The number of T cells under MMF treatment re-
mained even identical to nonischemic controls.
No B cells (OX-33) were present in controls nor in
the MMF-treated group (data not shown).
Correlation testing between functional, morphologic and
severity of leukocyte infiltrate showed no clear correlation
between different types of infiltrating cells and damage,
and an inverse correlation between infiltrating cells and
regeneration. The results of the parametric correlation
testing were similar to the non-parametric testing.
Effect of mycophenolate mofetil on tubular cell cul-
ture. A significant decrease in total cell number with
increasing MPA concentrations was observed. Cell pro-
liferation was almost abolished using 25 to 50 mol/L
MPA concentrations. Bromodeoxyuridine incorporation
was used as measurement of cell proliferation. With the
highest concentrations (25 to 50 mol/L) the prolifera-
tion dropped to 20% of the proliferation rate in fetal
calf serum 10% medium (Fig. 5).
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Fig. 4. Effect of mycophenolate mofetil
(MMF) on renal interstitial leukocyte infiltra-
tion in the outer stripe of the medulla of postis-
chemic rats (expressed as number/mm2). (A )
Polymorphonuclear (PMN) cells. (B ) ED-1,
monocytes/macrophages. (C ) W3/25, CD4
helper T cells. (D ) OX-8, suppressor/cytotoxic
T cells. Values are expressed as mean  SD.
*P 
 0.05; **P 
 0.01. Control is uninephrec-
tomy without ischemia on the remaining kid-
ney but with MMF.
Fig. 5. Effect of mycophenolate mofetil
(MMF) on tubular cell culture. (A ) Cell count
of human tubular cells in culture in the pres-
ence of different mycophenolic acid (MPA)
concentrations on day 3 and day 4. (B ) Prolif-
eration measured by bromodeoxyuridine in-
corporation in the presence of different con-
centrations MPA, expressed as percentage of
the proliferation in the control cultures.
DISCUSSION
Renal transplantation results in multiple proinflam-
matory insults to the kidney, including alloantigen-inde-
pendent I/R and alloantigen-dependent acute and chronic
rejection. All these insults are associated with endothe-
lial activation, leukocyte adhesion, and subsequent infil-
tration of the kidney, resulting in DGF, of which post
I/R ATN is the most prominent feature. Most kidneys
that exhibit DGF eventually recover, but the clinical
impression exists that this structural and functional re-
covery is delayed after cadaveric renal transplantation
compared to the nontransplant related ARF. In the set-
ting of posttransplant ATN, many transplant centers use
induction therapy with potent anti-T-cell antibody prep-
arations, which allows for delayed introduction of full-
dose cyclosporine or tacrolimus. The nephrotoxic effects
of high-dose cyclosporine or tacrolimus may extend the
duration of this ATN, although the cell histologic basis
of this hypothesis has not been studied yet.
The functional and morphologic approach of damage
and regeneration used in this nonalloimmune model of
ATN provides arguments that two commonly used im-
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munosuppressive drugs, CsA and MMF, given at the
time of I/R and at a clinical immunosuppressive dose,
affected this damage and recovery, each in a different
manner. CsA treatment was found to aggravate func-
tional and morphologic I/R-induced damage while MMF
treatment did not. Tubular cell proliferation under CsA
treatment was intact while under MMF treatment it was
clearly suppressed. Hence, proximal tubular regenera-
tion activity remained intact under CsA treatment but
ultimate differentiation after 10 days was delayed, most
likely because of the more pronounced immediate post-
I/R damage compared to their controls. In contrast, al-
though initial damage under MMF treatment was compa-
rable to controls, the proximal tubular regeneration was
clearly delayed, resulting in decreased differentiation
after 10 days. Both immunosuppressive treatments did
not affect the initial accumulation of intrarenal leuko-
cytes. However, between days 5 to10 after warm I/R,
the mononuclear cell infiltration/proliferation (first M
and later CD4 cells) was moderately depressed under
CsA treatment, in accordance with the finding of an
analog inhibition of leukocyte infiltration by CsA after
24 hours cold ischemia [26]. The combination of I/R with
MMF, however, resulted in an almost complete arrest
of the CD4 and CD8 cell proliferation at days 5 to
10 after warm I/R.
It is well known that a dose-related CsA-induced acute
renal dysfunction is a frequent adverse effect noted with
this effective immunosuppressive drug. Our experiments
of CsA administration in an immunosuppressive dose
of 10 mg/kg/day on a unilateral nephrectomy without
ischemia of the remaining native kidney showed no tubu-
lar damage. No signs of cell proliferation (PCNA positiv-
ity) or interstitial leukocyte infiltration were observed
during 10 days. On the contrary, the ischemic kidney has
been reported to be more susceptible to CsA, as result
of an additional (mediated by endothelin and other vaso-
active substances) vasoconstriction upon the existing
postischemic intrarenal vasoconstriction, rather than di-
rect tubular injury [11, 27]. The resulting ARF has shown
to be gradually enhanced after prolonged periods of isch-
emia (30 → 60 minutes) and increasing doses of CsA
(5→10→25 mg/kg/day) [27]. Since the introduction of
CsA in the 1980s, patients with ATN are thought to
benefit from conversion from CsA to polyclonal antilym-
phocytic preparations, since CsA has been shown to in-
crease the recovery time from transplant ATN [28–31].
In this study, however, no arguments for delayed func-
tional recovery or morphologic regeneration were found.
Indeed, proliferation activity post-ATN was not ham-
pered by CsA, in fact, it was slightly increased, most
likely related to the fact that there was more damage to
be repaired.
MMF had a negative impact on initial tubular cell
proliferation and consequently tubular regeneration.
Our in vitro results confirm our in vivo results using
clinically relevant MPA concentrations, which caused an
almost arrest of tubular cell proliferation. Meanwhile,
other investigators have made similar observations of
the adverse effect of MMF/MPA on cell growth and
chemokine release of tubular epithelial cells [32]. This
is an unreported and unexpected finding since MPA is
considered to be a lymphocyte-selective antiproliferative
agent, due to the potent inhibition of the de novo synthe-
sis of guanosine 5-triphosphate (GTP) upon which lym-
phocytes rely heavily [14]. Apparently, the possibility
exists that MMF also affects cells with high proliferative
capacity and activity like proximal tubular cells recov-
ering from ATN. The inhibition of smooth muscle cell
proliferation in rat aortic allografts by MMF [33] corrob-
orates the nonexclusive antiproliferative mode of action
of MMF on lymphocytes. In this respect, the gastrointes-
tinal side effects are probably also related to the action
of MPA on the fast-dividing cells enterocytes are. If the
thesis stands that T cells are important in damage and
regeneration [34], the negative effect of MMF on tubular
cell proliferation could also be explained as a conse-
quence of depressed lymphocyte proliferation, hence,
loss of regenerative potential. Indeed, it was previously
suggested [35, 36] that these infiltrating inflammatory
cells might be a source of growth-stimulating substances,
implying a role in the repair process after ARF.
Because of its performant immunosuppressive capac-
ity and because MMF does not seems to have a nephro-
toxic potential, its safe introduction immediately after
transplantation of even severe I/R damaged kidneys
could be considered. Indeed, the functional recovery of
the ischemic kidney seems not affected by MMF. In view,
however, of the negative impact of MMF on tubular
proliferation, hence, tissue regeneration, the results of
our study suggest to postpone the use of MMF until the
complete regeneration and recovery of kidney function
in severe I/R damaged kidneys. The use of MMF during
ATN may have a negative impact on long-term organ
function due to nonimmunologic reasons. How far the
negative impact on tubular cell proliferation and, hence,
tubular regeneration will affect long-term graft function
is an open question [37]. Literature, however, is abun-
dant on the detrimental effect of affected initial post I/R
morphology and function on ultimate graft function and
survival [2, 3, 38, 39].
As far as animal data can be extrapolated to humans,
the results of this study provide arguments for the more
optimal use of two important immunosuppressive drugs
in case of transplantation of severe I/R damaged kidneys.
The interference of MMF with regeneration of I/R dam-
aged renal allografts in rats, not being the case with
CsA, justify testing these observations in human renal
allotransplantation.
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